Oncology
Solid Cancer
3
Pipeline Programs↗
4
Active Trials↗
8
Companies Involved↗
Solid Cancer is an early-stage landscape with 3 programs across 8 companies. The most active players are Merck & Co., Teva, Meitheal.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
10
clinical trials
Completed4 · 40%
Recruiting3 · 30%
Terminated1 · 10%
Unknown status1 · 10%
Active, not recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)